2128 AIs indexed
↑↓ navigate
↵ open
AI precision medicine platform, now publicly traded
Tempus AI analyzes genomic sequencing, medical imaging, and clinical records to identify patterns in cancer care and cardiology, helping physicians make more personalized treatment decisions. It went public on Nasdaq in 2024, giving public markets a direct read on how well AI-driven precision medicine businesses can actually scale and turn a profit.
No reviews yet — be the first to share your experience.
It's easier when you're signed in — Altern helps you get more out of AI.
By continuing you agree to our Terms and Privacy Policy.